Maverix Medical acquires Cirrus Bio to advance lung cancer diagnosis

Maverix Medical, a leading lung cancer platform supported by Ajax Health, KKR, and Hologic, Inc., has officially announced its acquisition of Cirrus Bio, a company specializing in multiomic solutions for disease diagnosis and management, for an undisclosed sum. This strategic acquisition underscores Maverix Medical’s commitment to enhancing lung cancer diagnosis and treatment through advanced technological innovations.

Cirrus Bio, known for its contributions to the field of early cancer detection, has been pivotal in the development of diagnostics that play a critical role in improving clinical outcomes. The company’s founders, David Mallery (CEO) and Scott Morris (CSO), bring a wealth of experience from their previous ventures, including the Molecular Profiling Institute, Paradigm Diagnostics, Viomics, and the International Genomics Consortium, further strengthening Maverix Medical’s expertise in the oncology domain.

Concurrent with this acquisition, Maverix Medical has unveiled Maverix Dx, a new diagnostic division aimed at accelerating the development and commercialization of diagnostic tools specifically for lung cancer. David Mallery will lead Maverix Dx as CEO, with Scott Morris stepping in as CSO, signaling a robust strategy for advancing lung cancer diagnostics through innovative technologies, platform M&A, and strategic investments.

Duke Rohlen, Executive Chairman of Maverix Medical, emphasized the critical importance of early detection in lung cancer treatment, stating, “Lung cancer remains the largest cancer killer, by far. The only way to improve survival rates for this extremely aggressive disease is to catch it early and act decisively. This acquisition gives Maverix unparalleled technology, talent, and expertise in early cancer detection, and will serve as the foundation for a broader diagnostic portfolio with the potential to transform lung cancer care.”

Maverix Medical’s portfolio also includes Serpex Medical, a division focused on developing steerable technologies for precise lung tissue targeting, which has already achieved 510k clearance. Together, Maverix Dx and Maverix Med Device represent a comprehensive approach to lung cancer treatment, combining diagnostic and interventional tools to meet the needs of clinicians and patients alike.

David Mallery, CEO of Maverix Dx, highlighted the significant unmet clinical need in the lung cancer market, expressing enthusiasm for collaboration with other innovators to enhance care for lung cancer patients.

Supported by its financial sponsors and advisors, KKR and Hologic, Maverix Medical is poised for further growth in the development and commercialization of lung cancer solutions, inviting collaboration with innovators, entrepreneurs, clinicians, and industry leaders to join in their mission.